pmc logo image
Logo of bmjBMJ helping doctors make better decisionsSearchLatest content
Journal List > BMJ > v.324(7334); Feb 16, 2002

Formats:
BMJ. 2002 February 16; 324(7334): 393–396.
PMCID: PMC65532
Copyright © 2002, BMJ
Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study
Brent Taylor, professor of community child health,a Elizabeth Miller, head,b Raghu Lingam, research fellow,a Nick Andrews, statistician,b Andrea Simmons, research fellow,a and Julia Stowe, research associatea
aCentre for Community Child Health, Royal Free and University College Medical School, University College London Royal Free Campus, London NW3 2PF, bImmunisation Division, Public Health Laboratory Service, Communicable Disease Surveillance Centre, London NW9 5EQ
Contributors: BT and EM were responsible for the study design and are guarantors for the paper. BT, RL, and AS were responsible for case ascertainment and the review of case notes. NA undertook the statistical analyses. EM, RL, JS, and BT were responsible for data handling and processing. All authors contributed to writing the paper.
Correspondence to: B Taylor b.taylor/at/rfc.ucl.ac.uk
Accepted January 24, 2002.
Small right arrow pointing to: This article has been cited by other articles in PMC.
Abstract
Objectives
To investigate whether measles, mumps, and rubella (MMR) vaccination is associated with bowel problems and developmental regression in children with autism, looking for evidence of a “new variant” form of autism.
Design
Population study with case note review linked to independently recorded vaccine data.
Setting
Five health districts in north east London.
Participants
278 children with core autism and 195 with atypical autism, mainly identified from computerised disability registers and born between 1979 and 1998.
Main outcome measures
Recorded bowel problems lasting at least three months, age of reported regression of the child's development where it was a feature, and relation of these to MMR vaccination.
Results
The proportion of children with developmental regression (25% overall) or bowel symptoms (17%) did not change significantly (P value for trend 0.50 and 0.47, respectively) during the 20 years from 1979, a period which included the introduction of MMR vaccination in October 1988. No significant difference was found in rates of bowel problems or regression in children who received the MMR vaccine before their parents became concerned about their development (where MMR might have caused or triggered the autism with regression or bowel problem), compared with those who received it only after such concern and those who had not received the MMR vaccine. A possible association between non-specific bowel problems and regression in children with autism was seen but this was unrelated to MMR vaccination.
Conclusions
These findings provide no support for an MMR associated “new variant” form of autism with developmental regression and bowel problems, and further evidence against involvement of MMR vaccine in the initiation of autism.
What is already known on this topic
A “new variant” form of autism has been hypothesised, associated with developmental regression and bowel problems and caused or triggered by the MMR vaccination
This postulated association along with media attention has had a major adverse effect on public confidence in the vaccine
Although population studies have shown no association between autism and MMR vaccine it has been further postulated that various environmental or genetic cofactors are required for the effect
What this study adds
The proportion of children with autism who had developmental regression or bowel problems has not changed over the 20 years from 1979
Neither developmental regression nor bowel problems in children with autism was associated with MMR vaccination
No evidence was found for a “new variant” form of autism
Articles from BMJ : British Medical Journal are provided here courtesy of
BMJ Publishing Group

PubMed articles by these authors